Tonix Pharmaceuticals (NASDAQ: TNXP) through its subsidiary Tonix Medicines, has introduced two fast-acting migraine treatments, Zembrace® SymTouch ...

“Most people would agree that for xenotransplantation to become a reality, we’re going to need to use an anti-CD40L antibody ...

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive ini ...

Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary ...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

A newly designed therapy following an islet cell transplant could mean people with type 1 diabetes no longer need to inject ...

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and Valo ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat ...